Inclusion Criteria:

- 18 years of age or older

- Histologically proven prostate cancer

- Treatment plan is to administer long term ADT (androgen deprivation therapy).

- Patient must currently be treated with ADT for at least 2 weeks before enrollment in
trial, and for no more than 6 months. Patient treated with a maximum androgen
blockade strategy, combining an anti-androgen agent with a LHRH analog agent are
admissible to this protocol, but not patients treated only with an anti-androgen
agent alone.

- Written informed consent to participate in the trial.

Exclusion Criteria:

- Known hypersensitivity to Zoladex, Casodex (if applicable), or any component of these
product, or to other similar agents

- Severe cardiac disease (New York Heart Association class III or greater)

- Severe lung disease

- Uncontrollable pain

- Unstable bone lesion

- Any co-morbidity restraining the patient's ability to walk alone or to modify his
walking habits (eg Parkinson's disease, advanced multiple sclerosis, leg amputation,
...)

- Any concomitant condition that would make it undesirable, in the physician's opinion,
for the subject to participate in the trial or would jeopardize compliance with the
protocol.

- Any contraindication to undertake the 6-minutes walk test (unstable angina or
myocardial infarction during the previous month, a resting heart rate of more than
180, systolic blood pressure of more than 180, and a diastolic pressure of more than
100). The patient must have his cardiovascular conditions stabilized and controlled
before enrollment in the trial.

- Unwillingness or incapacity to consent to trial participation.